Conference
PSMA-PET/CT Registry for Recurrent Prostate Cancer (PREP): Initial findings from a single center.
Abstract
5064
Background: Several lesion-targeted therapies exist for locally recurrent or limited stage metastatic prostate cancer (PCa) post-radiotherapy (RT) and radical prostatectomy (RP). However, detection of disease sites is limited using conventional imaging (CI) including computed tomography (CT) and bone scan. Prostate specific membrane antigen (PSMA) targeting PET radiopharmaceuticals like [18F]DCFPyL may help detect disease …
Authors
Kapoor A; Zukotynski K; Tajzler C; Hoogenes J; Matsumoto E; Uy M; Bauman G; Metser U; Finelli A; Ding M
Volume
39
Pagination
pp. 5064-5064
Publisher
American Society of Clinical Oncology (ASCO)
Publication Date
May 20, 2021
DOI
10.1200/jco.2021.39.15_suppl.5064
Conference proceedings
Journal of Clinical Oncology
Issue
15_suppl
ISSN
0732-183X